2 March 2011
A new method of diagnosing prostate cancer has been developed by scientists in Surrey.
The researchers behind the new cancer diagnosis method claim that the test is far more accurate and less invasive than existing techniques.
Scientists from the University of Surrey hope that the diagnostic method will be clinically available within 18 months.
The urine test involves the detection of a chemical called EN2, which the scientists have shown is secreted by prostate cancers.
Professor Hardev Pandha, co-author of the new study, which was published in Clinical Cancer Research, said: "In this study we showed that the new test was twice as good at finding prostate cancer as the standard PSA test."
"Only rarely did we find EN2 in the urine of men who were cancer free," Professor Pandha said.
Meanwhile, a recent international study found that early hair loss could dramatically increase a man's prostate cancer risk.
1 Morgan, Richard et al. "Engrailed-2 (EN2): A Tumor Specific Urinary Biomarker for the Early Diagnosis of Prostate Cancer". Clinical Cancer Research. March 2011.
2 Giraud, Philippe et al. "Male pattern baldness and the risk of prostate cancer". Annals of Oncology. Tuesday, February 15th 2011.
Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.